Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ME2 | P23368 | 1/20 | 0.38 |
| ▸ | ME1 | P48163 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14137697 | 0.84 | PHGDH (0.48) | CA12CA2CA9AKR1C3CACNA1G | |
| SCHEMBL240195 | 0.81 | DHFR (0.48) | CA12CA2CA9AKR1C3CACNA1G | |
| SCHEMBL16788907 | 0.77 | SLC6A2 (0.37) | DRD2HTR2ASLC6A2MEN1HTT | |
| SCHEMBL28650484 | 0.76 | CA12 (0.65) | CA12CA2CA9AKR1C3CACNA1G | |
| SCHEMBL14924079 | 0.75 | MAPT (0.42) | KMT2A | |
| SCHEMBL13283424 | 0.73 | MAPT (0.61) | CA12CA2CA9AKR1C3CACNA1G | |
| SCHEMBL16249187 | 0.73 | ALDH1A1 (0.36) | CA12CA2CA9MEN1HTT | |
| SCHEMBL22875958 | 0.71 | CA12 (0.56) | CA12CA2CA9AKR1C3DHFR | |
| SCHEMBL2056173 | 0.71 | ALDH1A1 (0.57) | CA12CA2CA9AKR1C3DHFR | |
| SCHEMBL27236235 | 0.71 | MAPT (0.62) | CA12CA2CA9AKR1C3DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150158909-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150126747-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150105548-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150065542-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150031884-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140364617-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140364616-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (IL) | 2014-12-11 | — | — | US | disclosed |
| US-20140343286-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031884-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
| US-20140364616-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
| US-20140343286-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
| US-20150105548-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
| US-20140364617-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
| US-20150126747-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
| US-20150065542-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
| US-20150158909-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CA12 3463/4885CA2 4519/4885CA9 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.